ATHE

Announcements

Nothing here yet

Daily updates

• Alterity reported additional Phase 2 analyses showing ATH434 50 mg slowed functional decline in multiple system atrophy by about 52% versus placebo after adjustment for baseline CSF NfL.Oct 5, 2026

FDA designations

Nothing here yet

News

• Alterity Therapeutics received a new U.S. composition-of-matter patent for ATH434Aug 12, 2026
• Alterity Therapeutics confirmed a registrational pathway for ATH434 following FDA end-of-Phase 2 feedbackJul 8, 2026
• Alterity Therapeutics received positive FDA feedback after its second Type C meeting on the ATH434 Phase 3 program in multiple system atrophyApr 27, 2026
• Alterity presented new analysis from ATH434 Phase 2 trial data at the American Academy of NeurologyApr 22, 2026
• Alterity Therapeutics announced a late-breaker presentation at the American Academy of Neurology meetingApr 17, 2026